DWTX News & Events

As of December 31, 2025, Dogwood Therapeutics' cash and cash equivalents totaled $6.5 million. The Company believes that the cash and cash equivalents on hand at December 31, 2025 together with the net proceeds received in January 2026 of $11.4 million after deducting placement agent fees and offering expenses payable by the Company, is expected to fund operations through the Halneuron Phase 2b final data readout and into the fourth quarter of 2026.

"The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year," said Greg Duncan, CEO.

Dogwood Therapeutics announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain, HALT-CINP, trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026. "If the HALT-CINP study is successful, Halenuron would represent a new therapeutic agent for treating chemotherapy-induced neuropathic pain, a condition for which there are currently no approved therapies. There remains a great need for treatment options for the millions of patients suffering from chemotherapy-induced neuropathic pain and we continue to be encouraged by the rate of enrollment, interim outcomes and safety profile," said Dogwood Therapeutics Chief Medical Officer Michael Gendreau, M.D., Ph.D., "Against a history of failed clinical trials, the ongoing Halneuron(R) clinical trial has the potential to be the first statistically significant trial treating chemotherapy-induced neuropathic pain patients under FDA chronic pain study guidance."